Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics

Entasis Therapeutics Holdings Inc. (ETTX): $2.19

0.00 (0.00%)

POWR Rating

Component Grades













ETTX Stock Price Chart Interactive Chart >

Price chart for ETTX

ETTX Price/Volume Stats

Current price $2.19 52-week high $3.88
Prev. close $2.19 52-week low $1.40
Day low $2.19 Volume 31,700
Day high $2.20 Avg. volume 246,730
50-day MA $2.02 Dividend yield N/A
200-day MA $2.26 Market Cap 104.80M

Entasis Therapeutics Holdings Inc. (ETTX) Company Bio

Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.

ETTX Latest News Stream

Event/Time News Detail
Loading, please wait...

ETTX Latest Social Stream

Loading social stream, please wait...

View Full ETTX Social Stream

Latest ETTX News From Around the Web

Below are the latest news stories about Entasis Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ETTX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | February 2, 2022

Entasis gains on buyout proposal from Innoviva

Entasis Therapeutics (ETTX) is trading ~15% higher in the pre-market after announcing that its existing investor, Innoviva submitted a non-binding proposal to buy the shares it

Seeking Alpha | February 2, 2022

Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.

WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration o

Yahoo | February 2, 2022

Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022

WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and management’s participation are as follows: H.C. Wainwright BioConnect 2022Dates: January

Yahoo | January 10, 2022

-$0.26 EPS Expected for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) This Quarter

Equities research analysts expect that Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) will post earnings per share of ($0.26) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Entasis Therapeutics earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.26). Entasis Therapeutics posted earnings []

Dakota Financial News | December 14, 2021

Read More 'ETTX' Stories Here

ETTX Price Returns

1-mo N/A
3-mo 17.11%
6-mo 0.00%
1-year -20.07%
3-year -66.05%
5-year N/A
YTD 0.00%
2021 -11.34%
2020 -50.30%
2019 22.11%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4296 seconds.